The growing wave of copyright litigation against artificial intelligence developers is raising serious concerns about the long-term accessibility of AI tools for businesses and consumers. Lawsuits filed by authors, publishers, visual artists,
More
Snapchat has unveiled a new advertising format designed specifically for pharmaceutical marketers, making it easier to include required product disclosures within in-feed ads. The updated format allows pharma advertisers to attach product
More
Nuclear energy stocks have attracted growing investor interest as the surge in artificial intelligence infrastructure creates enormous new demand for reliable, low-carbon electricity. Data centres powering AI workloads require vast and uninterrupted
More
Alembic Pharmaceuticals has received a formal warning letter from the U.S. Food and Drug Administration targeting its bioequivalence research facility in Vadodara, India. The warning letter, dated July 10, 2026, follows an
More
Skadden Arps faces mounting political pressure over its conflict of interest concerns tied to its deal with the Trump administration and its simultaneous legal work for Intel. Senators Richard Blumenthal and Adam
More
Legendary investor Warren Buffett has long been regarded as one of the most reliable voices in finance during periods of market turbulence and uncertainty. Buffett’s approach to stock market crashes centres on
More
Apple (AAPL) has filed a lawsuit against OpenAI and two of its former employees, accusing them of stealing confidential information about its unreleased technologies and products. The iPhone maker filed the suit
More
The FTSE 100 climbed 64 points to 10,715.5 on Tuesday, with consumer-facing stocks and energy names providing the bulk of upward momentum in early trading. Burberry led the risers with a gain
More
A US federal court in California has granted summary judgment in favour of a pharmaceutical employer despite acknowledging the plaintiff had likely engaged in protected whistleblowing activity. The case, Han v. Pfizer
More
The London Stock Exchange has drawn up a worst-case scenario analysis warning that as many as 20 FTSE 100 companies could shift their direct listings to New York. The analysis, seen by
More